###### Key messages

-   Children with the obese-asthma phenotype may exhibit higher degrees of airflow obstruction and non-eosinophilic inflammation, which may respond more favourably to leukotriene receptor antagonists (LTRAs), than inhaled corticosteroids (ICS), due to their different modes of action; however, this has not yet been studied in children.

-   Children with excess weight were more likely to have an early management failure event (step-up in therapy or exacerbation) and respond to LTRA, but not low-dose ICS, when compared with their normal-weight counterparts.

-   These data support LTRA as a possible alternative therapy for mild asthma in children with excess weight who may have not previously responded to low-dose ICS; further prospective research is warranted to confirm findings.

Introduction {#s1}
============

Over the last few decades, the prevalence of obesity in paediatric asthma has risen rapidly, with an estimated 20% and 30% of children with asthma reported to be overweight and obese, respectively.[@R1] As its own distinct clinical phenotype,[@R3] obese children with asthma have been shown to be exacerbation-prone and difficult to manage.[@R2] As a result, these vulnerable children are often at a higher risk of school absenteeism[@R7] and decreased quality of life[@R8] when compared with their normal-weight counterparts.[@R4] Along with increased morbidity, obese patients with asthma may have a suboptimal therapeutic response to inhaled corticosteroids (ICS),[@R6] which constitute the current gold standard for asthma management in children.[@R11]

Poor response to ICS among obese patients has been hypothesised to be due to altered lung function and inflammatory processes.[@R4] The excess weight-induced mechanical stress placed on the thoracic cage can lead to higher degrees of airflow limitation, which some speculate may lead to reduced peripheral lung deposition of inhaled therapies.[@R9] There is also support for an alternative inflammatory process in obese-asthma that is independent of the classical Th2 eosinophilic-mediated pathway,[@R14] with eosinophilic phenotypes known to be corticosteroid-responsive in patients with asthma without refractory disease. As the obese-asthma inflammatory pathway may be mediated by a neutrophilic mechanism,[@R17] experts have questioned the applicability of the current treatment guidelines to patients with excess weight,[@R18] recommending low-dose ICS as the first-line Step-2 maintenance therapy for mild persistent asthma.[@R19] Nevertheless, findings supporting a differential response attributed to weight status in children have yet to be confirmed.

Leukotriene receptor antagonists (LTRAs) are a second-line Step-2 oral maintenance monotherapy that inhibit both eosinophil-mediated and neutrophil-mediated inflammation and whose action is independent of lung mechanics to achieve therapeutic targets; it may thus serve as an alternative therapy in patients with excess weight.[@R21] Given the paucity of studies evaluating the comparative effectiveness of LTRA monotherapies by weight status in children with asthma, low-dose ICS remains the preferred first-line Step-2 therapy across guidelines. Thus, the potential benefits of LTRA versus ICS in terms of achieving control and preventing exacerbation in children with excess weight have not been established.

The primary objective of this study was to assess if weight status modifies the response to low-dose ICS and LTRA monotherapy, specifically by evaluating whether the association between Step-2 therapies and time-to-management failure is modified by body mass index (BMI) percentile in children with asthma. We hypothesised that weight-related changes to lung physiology and mechanics would lead to a differential response to Step-2 therapies in children with higher BMI status.

Methods {#s2}
=======

Research design {#s2-1}
---------------

A historical cohort study was conducted using a database that linked clinical chart data to Quebec administrative health and drug claims databases for the purposes of evaluating the effectiveness of different asthma maintenance therapies and risk factors for poor outcomes. The Paediatric Asthma Database contained 15 147 clinical records of 4621 children who visited the Asthma Centre of the Montreal Children's Hospital between January 2000 and December 2007.

Patient and public involvement {#s2-2}
------------------------------

Because this is a database study, the research question and outcomes measured were not informed by patients, nor were patients involved in the recruitment to or conduct of the study. As all data were anonymised, study results cannot be directly disseminated to the patients included in this study.

Data sources {#s2-3}
------------

The Paediatric Asthma Database included detailed information on sociodemographics, asthma diagnosis, severity and control indicators as assessed by the consulting asthma specialist, environmental exposures, lung function test results and medical chart records of all prescribed asthma maintenance and/or rescue treatments, with the indication for medication use clearly labelled, for each visit at the Asthma Centre. Patient records from the Paediatric Asthma Database were linked to the hospital admission (MED-ECHO), Régie de l'assurancemaladie du Québec (RAMQ) medical service and prescription claims administrative databases. The RAMQ medical service database contains information on the type, location of service delivery and diagnostic codes using the International Classification of Diseases 9th and 10th revisions (ICD-9; ICD-10) for all medical services billed by physicians. The MED-ECHO database includes admission and discharge codes for all hospitalisations in Quebec. Children are provided universal access to all healthcare services in Quebec. Lastly, the RAMQ prescription claims database contains data on all drugs dispensed to patients enrolled in the Public Drug Insurance Plan (42% of Quebec residents).[@R24]

Study population {#s2-4}
----------------

Children were included if they were aged 2--18 years, consulted the Asthma Centre during the study period 2000--2007, had an asthma diagnosis confirmed by a specialist, and were prescribed low-dose ICS or LTRA (Step-2) maintenance monotherapies as documented in the medical chart at the index visit date. Patients were excluded if they were diagnosed with bronchopulmonary dysplasia or cystic fibrosis or were not enrolled in the public drug or health insurance plan at least 6 months prior to and 3 months following the visit date. The study population included children who were initiating or continuing a prescription of low-dose ICS or LTRA. Children initiating ('incident' users) and continuing therapy ('prevalent' users) were defined as those who had no claims and at least one claim for low-dose ICS or LTRA, respectively, in the 6 months preceding the index date ('lookback period'). Children who had claims for medium-dose or high-dose ICS or ICS in combination with long-acting beta-2 agonists (LABAs) or LTRA during the lookback period were excluded. The cohort entry (index) date was defined as the date at which patients met all inclusion criteria. We included all visit dates eligible for cohort entry based on the above criteria; thus, some children contributed multiple entry dates (also known as 'trials'[@R25]) to the cohort and thus could contribute data to both ICS and to LTRA at different points in time. Follow-up ended at the outcome date, end of insurance coverage, 1-year post index date or 31 December 2007, whichever occurred first.

Outcome {#s2-5}
-------

Management failure was defined as a composite endpoint that included any of the following events: (1) a step-up in maintenance therapy, that is, higher dose ICS, ICS/LABA or ICS/LTRA combination therapy dispensed during follow-up; (2) a short course of oral corticosteroids; (3) an acute care visit; or (4) a hospital admission for an asthma exacerbation (ICD-9 493.X; ICD-10 J45.X). We instated a lag of 3 days following cohort entry before assessing the outcome to exclude the possibility of pre-existing exacerbations.

Exposures {#s2-6}
---------

### Weight status: BMI percentile {#s2-6-1}

BMI percentiles were computed using Z-scores with age- and sex-specific WHO growth reference values from the height and weight measurements documented by trained healthcare professionals at the Asthma Centre index visit.[@R26]

### Treatment {#s2-6-2}

A time-varying exposure definition was implemented to classify Step-2 maintenance therapy use throughout follow-up. Children dispensed low-dose ICS, that is, \<200 μg/day (\<250 μg/day if ≥12 years old) of hydrofluoroalkane-propelled beclomethasone dipropionate or equivalent measured ex-valve,[@R20] were classified as exposed to low-dose ICS monotherapy for the duration of the claim. Children dispensed LTRA (montelukast or zafirlukast) were classified as exposed to LTRA monotherapy for the duration of the claim. If the ICS daily dose documented in the claims database was discordant with Asthma Centre records, the expected duration of the drug claim was adjusted to better reflect the prescribed daily dose as documented in the medical charts at the index date. If a child held an active prescription claim for a Step-2 maintenance therapy at the index date, he/she was considered exposed from cohort entry until the expected completion date of that pre-existing drug claim. Gaps of no therapy, that is, the time defined by the absence of claims for both low-dose ICS and LTRA, were classified as periods of 'treatment non-compliance', which served as a reference group.

Time-fixed and time-varying confounders {#s2-7}
---------------------------------------

Sociodemographic variables (age, sex, ethnicity and average family income estimated from census data using six-digit postal codes), user type (incident vs prevalent), asthma phenotype (persistent vs non-persistent), respiratory comorbidities (including atopy, recurrent otitis, sinusitis, pneumonia, gastro-oesophageal reflux, obstructive sleep apnoea, bronchopulmonary aspergillosis, vocal cord dysfunction or dysphagia), exposure to cigarette smoke and morbidity (number of exacerbations in the preceding year) were documented at the index visit and defined as time-fixed confounders. Time-varying confounders included physicians' global assessment of asthma severity and prebronchodilator percent predicted forced expiratory volume in 1 s (FEV~1~) test values as they were updated at each visit to the Asthma Centre. In some children, higher dose ICS was prescribed as a rescue therapy by the Asthma Centre physician, which could have confounded treatment effects. Thus, we also controlled for higher dose ICS rescue therapy use, where the child was classified as using the rescue therapy from the date at which he/she claimed the rescue medication (as prescribed in medical charts) until the end of follow-up, and season to account for viral-induced and allergy-induced worsening of asthma symptoms.

Statistical analysis {#s2-8}
--------------------

We used multiple imputations to address missing data for BMI percentile (1.2%), ethnicity (9.3%), percent predicted FEV~1~ (13.1%), exposure to smoking (22.6%) and family income (22.9%) at the index date. We did not test differences in baseline characteristics between treatment groups, as recommended by the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. We fit extended Cox models to obtain conditional associations for Step-2 maintenance therapies and a 10-unit increase in BMI percentile at baseline with respect to the hazard of management failure, while adjusting for all measured confounders. We also fit marginal structural Cox models for time-varying treatments, which have the added advantage of correcting for time-dependent confounding.[@R27] To correct for possible selection bias potentially induced by time-dependent confounding and losses to follow-up, we fit two separate propensity score models, for treatment use and censoring, respectively, at each follow-up week interval, conditional on all measured confounders and covariates. We then computed stabilised inverse probability of treatment and censoring weights for each follow-up week interval.[@R27] We used the product of these weights in the estimation of the final marginal HRs for treatment.[@R27] In the marginal model, the weighted approach enables the estimation of an HR that compares the marginal hazards of time-to-management failure between treatment categories (non-compliant, low-dose ICS or LTRA) had all patients been consistently taking their LTRA monotherapy, their low-dose ICS monotherapy or been non-compliant (ie, not exposed to any treatment), throughout the follow-up period. If the propensity score model is correctly specified, the marginal structural model emulates a randomised controlled trial contrasting the expected time-to-event outcomes of each treatment arm (no treatment, low-dose ICS and LTRA monotherapy) had all patients remained in their assigned arm throughout follow-up---an estimate that reflects what would happen in an ideal setting (efficacy).[@R29] Conversely, the conditional model estimates an HR comparing the hazards of time-to-management failure between patients exposed to ICS, LTRA or non-compliance at observed event times $T$, given patients' observed treatment (patterns of use) and covariate histories, as well as having remained under observation until time $T$---an estimate that is reflective of real life (effectiveness).

Violations to the proportional hazards assumption were investigated by visually inspecting the scaled Schoenfeld residuals plot and confirmed with the likelihood ratio test (LRT) for improved fit when an interaction term with time was included in the model. To obtain conditional and marginal treatment HRs for different weight status categories, interaction terms between treatment and BMI percentile at baseline was included. When evaluating whether treatment effects were modified by BMI percentile, we computed the relative excess risk due to interaction (RERI)[@R31] and the LRT for the marginal and conditional models to assess interaction on the additive and multiplicative scales, respectively.

Based on the data distribution, BMI percentiles were classified ad hoc into normal (BMI ≤80th percentile) and excess weight (BMI \>80th percentile) using the median as the cut-off point to improve statistical power; this dichotomisation was used to estimate joint effects and the specific survival curves for each Step-2 therapy and weight category combination, as well as the treatment (ICS or LTRA) HRs stratified by weight category. Sensitivity analyses were conducted to verify (1) potential non-linear relationships between BMI percentile and treatment effects with restricted cubic splines; (2) effects observed only in those with persistent asthma; and (3) the robustness of methods for handling missing data (multiple imputations vs complete case analysis). In addition, subgroup analyses explored whether findings differed in incident and prevalent users. Robust SEs were used to account for the inclusion of multiple 'person-visits' and the weights in the marginal model. Data management was performed with SAS V.9.4, and survival curves were illustrated using Stata Statistical Software V.13, while other analyses were performed using RStudio V.1.0.44.

Results {#s3}
=======

Of the total 15 147 visits (N=4621 patients) in the Paediatric Asthma Database, 518 (n=342) person-trials were included in the final cohort ([figure 1](#F1){ref-type="fig"}), of whom 85 and 433 were prescribed LTRA and low-dose ICS at the index visit, respectively. The number of visits contributed by each patient is illustrated in online [supplemental figure e-1](#SP1){ref-type="supplementary-material"}.
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![Study population flow chart. CF, cystic fibrosis; BPD, bonchopulmonary dysplasia; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.](bmjresp-2019-000401f01){#F1}

Children included in the cohort were mostly male (56%), aged 5 years and older (87.5%), with a mean treatment period of 11 weeks (ranging from 0 to 52 weeks). Children prescribed low-dose ICS had more moderate-severe asthma and comorbidities, as well as higher healthcare utilisation in the previous year, than those prescribed LTRA. On average, children prescribed LTRA were older, had higher family income, and reported more exercise-triggered symptoms compared with those prescribed low-dose ICS ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of incident and prevalent users prescribed Step-2 maintenance therapy

  Baseline characteristics                           LTRA (n\*=85)     ICS (n\*=433)
  -------------------------------------------------- ----------------- -----------------
  Age,$\overline{x} \pm \sigma$                      11.3 ± 3.9        9.7±4.2
  Female, n (%)                                      42 (49.4)         186 (43.0)
  Ethnicity, n (%)                                                     
   Caucasian                                         68 (80.0)         261 (60.3)
   Black                                             8 (9.4)           64 (14.8)
   Other                                             9 (10.6)          108 (24.9)
  Income, M±IQR                                      45 684 (19 929)   40 187 (19 527)
  Weight status, n (%)                                                 
   BMI ≤80th percentile                              44 (51.8)         218 (50.4)
   BMI \>80th percentile                             41 (48.2)         215 (49.6)
  Exposure to cigarette smoke, n (%)                 41 (48.2)         121 (27.9)
  \% Predicted FEV~1~,$\overline{x} \pm \sigma$      99±12.8           98±14.1
  Asthma phenotype, n (%)                                              
   Episodic/Seasonal                                 37 (43.5)         174 (40.2)
   Persistent                                        48 (56.5)         259 (59.8)
  Global assessment of severity, n (%)                                 
   Mild                                              84 (98.8)         340 (78.5)
   Moderate-severe                                   1 (1.2)           93 (21.5)
  Exacerbations for asthma in previous year, n (%)                     
  Acute care visits                                                    
   0                                                 15 (28.6)         64 (14.78)
   1                                                 18 (20.0)         99 (22.86)
   2                                                 22 (31.4)         104 (24.01)
   ≥3                                                30 (20.0)         142 (32.8)
  Hospitalisations                                                     
   0                                                 83 (97.7)         368 (85.0)
   ≥1                                                2 (2.3)           65 (15.0)
  Oral corticosteroids                                                 
   0                                                 79 (94.3)         298 (68.8)
   ≥1                                                6 (5.7)           135 (31.2)
  Asthma-related comorbidities, n (%)†                                 
   None                                              55 (64.7)         202 (46.7)
   Atopy‡                                            26 (30.6)         214 (49.4)
   Upper/Lower respiratory conditions§               7 (8.2)           43 (9.9)
  Triggers, n (%)†                                                     
   Viral                                             54 (63.5)         310 (71.6)
   Allergic                                          38 (44.7)         191 (44.1)
   Effort                                            53 (62.4)         189 (42.7)
   Temperature                                       7 (8.2)           66 (14.9)

\*Number of person-trials.

†Categories are not mutually exclusive.

‡Atopic conditions comprise eczema, allergic rhinitis, conjunctivitis and food allergies.

§Chronic upper or lower respiratory tract comorbidities include a history of recurrent otitis, sinusitis, pneumonia, gastro-oesophageal reflux disease, obstructive sleep apnoea, bronchopulmonary aspergillosis, vocal cord dysfunction or dysphagia.

BMI, body mass index; FEV~1~, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.

There were a total of 338 management failures during the 14 529 trial-weeks of follow-up. The incidence rates for management failure remained relatively stable between prescribed treatment at the index visit (ICS vs LTRA), regardless of the number of visits contributed by the child in the analysis; however, the incidence rate was elevated for children using LTRA during follow-up who contributed two or more visits compared with those contributing a unique visit (online [supplemental tables e-1a and e-1b](#SP2){ref-type="supplementary-material"}). In the main effects model, the conditional and marginal hazard of management failure increased by 6% (HR 1.06; 95% CI 1.01 to 1.10) and 5% (HR 1.05; 95% CI 1.01 to 1.10) for every 10-unit increase in BMI percentile, respectively ([table 2](#T2){ref-type="table"}). While not statistically different, results suggested a trend towards an overall poorer response to LTRA than to low-dose ICS (conditional HR 1.15, 95% CI 0.68 to 1.61; marginal HR 1.52, 95% CI 0.72 to 3.22) with respect to time-to-management failure.
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###### 

Conditional and marginal model estimates for time-to-management failure

  Models                                              Average HR (95% CI)\*   
  --------------------------------------------------- ----------------------- -----------------------
  **Main** **e** **ffects** **m** **odel**                                    
  BMI percentile (for every 10 units)                 1.06 (1.01 to 1.10)     1.05 (1.01 to 1.10)
  ICS vs treatment non-compliance                     0.91 (0.69 to 1.20)     0.93 (0.70 to 1.23)
  LTRA vs treatment non-compliance                    1.05 (0.68 to 1.61)     1.11 (0.72 to 1.70)
  LTRA vs ICS                                         1.15 (0.74 to 1.80)     1.52 (0.72 to 3.22)
  **Model with** **i** **nteraction** **t** **erm**                           
  BMI percentile (for every 10 units)                 1.09 (1.03 to 1.16)     1.08 (1.02 to 1.15)
  ICS vs treatment non-compliance                     1.45 (0.66 to 3.16)     1.37 (0.61 to 3.10)
  LTRA vs treatment non-compliance                    7.94 (2.56 to 24.69)    4.62 (1.27 to 16.88)
  ICS × BMI percentile                                0.94 (0.85 to 1.03)     0.95 (0.86 to 1.04)
  LTRA × BMI percentile                               0.78 (0.67 to 0.91)     0.83 (0.70 to 0.99)
  *LRT p* *value* *†*                                 \<0.001                 \<0.001
  *RERI ICS* *×* *BMI percentile* *‡*                 −0.06 (−0.16 to 0.04)   −0.05 (−0.14 to 0.05)
  *RERI LTRA* *×* *BMI percentile* *‡*                −1.29 (−3.55 to 0.97)   −0.52 (−1.76 to 0.71)

\*After accounting for age, sex, ethnicity, income, user type, global assessment of severity score, number of exacerbations in previous year, exposure to smoke, asthma-related comorbidities, triggers, % predicted FEV~1~, ICS rescue use and season.

†LRT assesses improved goodness of fit when comparing nested models (the model with interaction terms vs the main effects model); a p value \<0.05 indicates a statistically significant improved fit, that is, explaining a greater proportion of the variance in the outcome, and the likely presence of effect measure modification on the multiplicative scale.

‡RERI=HR~Therapy×BMI~ -- HR~Therapy~ -- HR~BMI~ +1; a negative RERI can be interpreted as the hazard reduction due to interaction on the additive scale (subadditivity), adjusted for measured confounders.

BMI, body mass index; FEV~1~, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LRT, likelihood ratio test; LTRA, leukotriene receptor antagonist; RERI, relative excess risk due to interaction.

In the conditional and marginal models that include an interaction term between Step-2 therapy and BMI percentile, a clinically relevant reduction in the risk of management failure was not observed with increasing BMI percentile among ICS users. In contrast, for children treated with LTRA, an additional 22% (HR 0.78; 95% CI 0.67 to 0.91) and 17% reduction (HR 0.83; 95% CI 0.70 to 0.99) in the conditional and marginal hazards of management failure were observed for every increase of 10 BMI percentile units, respectively. Of note, inclusion of the interaction term of treatment by BMI percentile significantly improved the fit (LRT p\<0.001) in both models, indicating the presence of treatment effect modification on the multiplicative scale; the RERIs suggested a trend towards subadditivity, that is, the joint effects of BMI and treatment were less than the sum of their individual effects on the additive scale, which was most pronounced for LTRA (marginal RERI −0.52; 95% CI −1.76 to 0.71) relative to ICS (marginal RERI −0.05; 95% CI −0.14 to 0.05) ([table 2](#T2){ref-type="table"}). In the spline sensitivity analysis, a non-linear relationship between BMI percentile and the hazard of management failure was visually evident for ICS users, but not LTRA users, indicating that models assuming a linear relationship with BMI may overestimate the beneficial effect of ICS at an elevated weight status, suggesting a blunted response to ICS at higher BMI percentiles (online [supplemental figure e-2](#SP1){ref-type="supplementary-material"}).

The average conditional and marginal HRs for different treatment--weight status categories (≤80th vs \>80th percentile) were also estimated in relation to a common reference group, namely normal-weight children who were non-compliant to treatment ([table 3](#T3){ref-type="table"}). Compared with this reference group, the marginal HRs of management failure for LTRA were 1.72 (95% CI 1.01 to 2.93) for normal-weight and 1.14 (95% CI 0.61 to 2.13) for excess-weight patients. For normal-weight and excess-weight children on ICS, the estimates were 0.96 (95% CI 0.62 to 1.48) and 1.21 (95% CI 0.84 to 1.74), respectively, suggesting a trend towards a reduced response to ICS with higher BMI. Children with excess weight who were also non-compliant to treatment had a marginal HR of 1.38 (95% CI 1.00 to 1.89). The conditional model demonstrated similar trends ([table 3](#T3){ref-type="table"}).

###### 

Conditional and marginal joint effects of treatment and weight status on time-to-management failure

  Treatment                  Weight status           Events/Visit-weeks (n)   Average HR (95% CI)\*   
  -------------------------- ----------------------- ------------------------ ----------------------- ---------------------
  LTRA monotherapy           BMI \>80th percentile   12/563                   1.09 (0.60 to 2.00)     1.14 (0.61 to 2.13)
                             BMI ≤80th percentile    16/470                   1.69 (1.00 to 2.88)     1.72 (1.01 to 2.93)
                             Overall                 28/1033                                          
  Low-dose ICS monotherapy   BMI \>80th percentile   59/2184                  1.18 (0.83 to 1.69)     1.21 (0.84 to 1.74)
                             BMI ≤80th percentile    61/2771                  0.92 (0.60 to 1.43)     0.96 (0.62 to 1.48)
                             Overall                 120/4955                                         
  Treatment non-compliance   BMI \>80th percentile   95/3531                  1.40 (1.03 to 1.92)     1.38 (1.00 to 1.89)
                             BMI ≤80th percentile†   96/5010                  1.00 (reference)        1.00 (reference)
                             Overall                 191/8541                                         

\*After accounting for age, sex, ethnicity, income, user type, global assessment of severity score, number of exacerbations in previous year, exposure to smoke, asthma-related comorbidities, triggers, % predicted FEV~1~, ICS rescue use and season.

†Reference category.

BMI, body mass index; FEV~1~, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.

The HRs for different treatment comparisons stratified by normal weight and overweight subgroups are displayed graphically in [figure 2](#F2){ref-type="fig"}. Survival curves for treatment and weight status category are illustrated in [figure 3](#F3){ref-type="fig"}. Trends and conclusions remained consistent in incident and prevalent users, when restricting to patients with persistent asthma, and different methods of handling missing data (online [supplemental tables e-2, e-3, and e-4](#SP2){ref-type="supplementary-material"}).

![Conditional and marginal treatment HRs (95% CI) stratified by weight category and overall averages. The reference groups are treatment non-compliance (all weight categories), treatment non-compliance among those with a BMI ≤80th percentile ('normal weight') and treatment non-compliance among those with a BMI \>80th percentile ('overweight'). BMI, body mass index; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.](bmjresp-2019-000401f02){#F2}

![Marginal probability of not experiencing a management failure event, that is, remaining adequately controlled, for each weight status--treatment combination. BMI, body mass index; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.](bmjresp-2019-000401f03){#F3}

Discussion {#s4}
==========

In this cohort of children with asthma treated with Step-2 therapy, BMI percentile was associated with an overall increased risk of management failure. Our findings suggest a differential response to Step-2 maintenance therapies by weight status for LTRA. Whereas there was an overall greater risk of failure in children treated with LTRA, this was not observed in children with excess weight. No statistically significant interaction with weight was observed in children treated with low-dose ICS, although there was a trend for reduced response in children with higher BMIs.

Obesity is an established risk factor for poor control. We observed an overall 5%--6% increased risk of Step-2 monotherapy treatment failure for every 10-unit increase in BMI percentile in the main effects model and up to a 40% higher risk of failure in overweight children who were non-compliant to treatment in the analysis displaying HRs for different treatment--weight status categories. This is consistent with a recent meta-analysis of observational data including 46 070 children, which identified obesity as a significant determinant of asthma exacerbations (OR 1.17; 95% CI 1.03 to 1.34).[@R5] Our results also suggest a differential response to Step-2 monotherapy by weight status. When compared with periods of treatment non-compliance and contrary to our hypothesis, no statistically significant treatment effect modification by weight was observed with ICS. However, whereas there was a trend towards overall poorer response for LTRA compared with low-dose ICS in the main effects model, a greater response to LTRA was observed at higher BMI percentiles when weight status was taken into account as a potential treatment response modifier in the interaction model. In other words, ICS and LTRA monotherapies seemed to be equally effective at prolonging time-to-management failure in children with a BMI \>80th percentile, while low-dose ICS appeared to be, on average, more effective than LTRA in children with a BMI ≤80th percentile as graphically displayed.

To our knowledge, no previous studies have evaluated the differential response to LTRA relative to low-dose ICS by weight status in children, and the marginal structural models applied in this study are novel to paediatric asthma, although this approach has been previously implemented in a few adult asthma studies.[@R32] Nevertheless, in a post-hoc analysis of a placebo-controlled randomised trial with 1041 children initiating low-dose ICS, Forno *et al* [@R10] reported that lung function and bronchodilator response were diminished by 0.4% and 0.25% for every 10% increase in BMI percentile, respectively. The authors did not evaluate response to LTRA for different BMIs. Yet, consistent with our findings, they demonstrated that normal-weight children initiating ICS experienced a significant reduction in the number of emergency department visits or hospitalisations for asthma during follow-up, whereas no improvement was observed in those with excess weight.[@R35] Post-hoc analyses of adult randomized controlled trials also reported a differential effect of Step-2 therapy across weight status, although results were conflicting. Peters-Golden *et al* [@R36] noted that the effect of LTRA on asthma control days remained constant across weight categories, while that of low-dose ICS decreased with increasing BMI. Normal-weight adult patients randomised to low-dose ICS had a significantly greater percentage of asthma control days than those randomised to LTRA; however, this difference did not persist in patients with excess weight, consistent with our findings.[@R36] Similarly, Sutherland *et al* [@R37] showed that patients with excess weight were more likely to experience a reduced response to ICS monotherapy in relation to exhaled nitric oxide levels when compared with their normal-weight counterparts, although without increasing the risk of exacerbation; in contrast, a reduced response to LTRA was not observed among those with higher BMI.[@R37] In two other post-hoc analyses of RCTs, low-dose ICS was superior to LTRA with respect to improving FEV~1~, symptom scores and short-acting beta-2 agonist use across all weight categories, although it was suggested that response to both treatments may be attenuated at higher BMIs.[@R38] Our paediatric study further supports ICS as a more effective option than LTRA in normal-weight children but not in overweight children, which aligns with Peters-Golden *et al*,[@R36] where the response to LTRA was observed to increase with higher BMI.

There are several mechanisms underlying a possible differential response to LTRA and/or ICS by weight status in children. First, obesity has been shown to adversely affect pulmonary physiology by changing the elastic properties of the chest wall, leading to reduced forced vital capacity, FEV~1~ and peripheral airway diameter.[@R40] In some children, the excess weight placed on the thoracic cage may inhibit lung expansion, which could lead to reduced absorption and deposition of inhaled therapies in the lower airways. Anderson and Lipworth[@R9] showed that cortisol suppression was reduced in adults with asthma who were overweight when compared with their normal-weight counterparts, which they attributed to possible insufficient absorption and deposition of inhaled steroids.[@R9] Perhaps, in children with higher weight-related lung compression, LTRA could offer an additional benefit over ICS as its efficacy is not affected by lung mechanics. Second, obese patients may exhibit an inflammatory process that is phenotypically different from the traditional Th2-dependent pathway---the latter underpins guidelines recommending low-dose ICS as a first-line Step-2 maintenance therapy. Moreover, some studies have suggested an airway inflammatory process partially mediated by leukotrienes, which may explain the increased response to LTRA at higher BMI percentiles in our study.[@R16] Lastly, there is some evidence of shared genetic factors in the phenotypic variation of both obesity and asthma, including response to treatment.[@R41] Polymorphisms in the B2-adrenergic and glucocorticoid receptor genes, as well as tumour necrosis factor-α, have been linked to asthma, obesity, and in some cases treatment response.[@R42] Whatever the mechanism explaining the observed greater response to LTRA in those with excess weight, the findings suggest considering LTRA in patients with asthma with excess weight, if not as first line Step-2 therapy, at least as an alternative in those with suboptimal response to ICS, prior to step-up therapy.

The strengths of this study include specialist-diagnosed asthma (vs self-report), the availability of clearly recorded data on Asthma Centre physician prescriptions (type, dosage, and intended use of the asthma medication), as well as updated information on severity indicators throughout the follow-up period, which enabled the implementation of the marginal structural Cox model. In addition to a more intuitive interpretation, the marginal structural model generates a marginal HR that avoids biases arising from complicated cases of time-dependent confounding and non-collapsibility that are inherent to the conditional HR.[@R45] Study findings should be interpreted in light of several limitations. Despite the inclusion of multiple covariates to adjust for differences between treatment groups, we suspect residual confounding by indication in this retrospective cohort analysis; indeed, children using their Step-2 therapies had similar or slightly higher HRs of management failure than those who were non-compliant to treatment, suggesting that the latter may have stopped using prescribed therapy because of milder symptoms compared with those who continued therapy. This residual confounding was minimised in the prevalent user subgroup results, since these children likely had a more persistent phenotype. Yet the consistency of findings in relation to the overall and treatment-specific effects by weight status on management failure in the subgroup analyses, irrespective of the marginal or conditional models, and the use of BMI as continuous or dichotomous variables, attests to the robustness of the results. We could not perform additional subgroup analyses based on age and sex due to our small sample sizes; however, we acknowledge the possibility that the effect of BMI percentile on time-to-management failure may vary across prepubertal, pubertal and postpubertal children due to developmental differences and hormones affecting adiposity and growth trajectory.[@R4] Finally, because participants had to be enrolled in the Quebec public drug insurance programme, 49% of the original cohort were excluded, resulting in a reduced sample size and lower statistical power as well as an under-representation of children from higher income families who were privately insured. Moreover, participants were recruited from a tertiary care asthma clinic. Therefore, our findings may not be generalisable to children with asthma covered by private drug insurance, of higher socioeconomic status, or those not receiving specialised care.

In conclusion, our findings provide clinical insight into the association between weight status and treatment response in children initiated on Step-2 maintenance monotherapy. Children with higher BMI percentiles were overall more likely to experience early management failure despite Step-2 maintenance therapythan their normal-weight counterparts. Of interest, LTRA seems to achieve best response at higher BMI percentiles. While higher BMI status appears to be associated with a trend towards a reduced response to low-dose ICS, this association did not reach statistical significance. While addressing weight-reduction approaches to overcome challenges associated with obese-asthma, consideration may be given to LTRAs as an alternative Step-2 monotherapy in children with excess weight or at least in those with suboptimal response to low-dose ICS. However, given the limitations of this retrospective cohort study, further research is warranted to determine whether ICS and LTRA monotherapies are comparable in terms of prolonging time-to-management failure in higher risk obese children with asthma.
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